Here, we present the results from a retrospective analysis, with the purpose of evaluating the safety and feasibility of nivolumab and radiotherapy (RT) concomitant association in metastatic kidney and lung cancer patients.
Benefit of ablative versus palliative-only radiotherapy in combination with nivolumab in patients affected by metastatic kidney and lung cancer / Desideri I., Francolini G., Scotti V., Pezzulla D., Becherini C., Terziani F., Delli Paoli C., Olmetto E., Visani L., Meattini I., Greto D., Bonomo P., Loi M., Detti B., Livi L.. - In: CLINICAL & TRANSLATIONAL ONCOLOGY. - ISSN 1699-048X. - STAMPA. - 21:(2019), pp. 933-938. [10.1007/s12094-018-02005-7]
Benefit of ablative versus palliative-only radiotherapy in combination with nivolumab in patients affected by metastatic kidney and lung cancer
Desideri I.;Francolini G.;Scotti V.;Pezzulla D.;Becherini C.;Terziani F.;Delli Paoli C.;Olmetto E.;Visani L.;Meattini I.;Greto D.;Bonomo P.;Loi M.;Livi L.
2019
Abstract
Here, we present the results from a retrospective analysis, with the purpose of evaluating the safety and feasibility of nivolumab and radiotherapy (RT) concomitant association in metastatic kidney and lung cancer patients.
| File | Dimensione | Formato | |
|---|---|---|---|
|
2018_Desideri I_Clinical Transl Oncol.pdf
Accesso chiuso
Descrizione: Paper
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
670.82 kB
Formato
Adobe PDF
|
670.82 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
